Quarterly ResultOct 29, 2026, 04:14 PM
Supernus Q3 Revenue $226.8M (+18% YoY); Merger with Indivior to Close Nov 2
AI Summary
Supernus Pharmaceuticals announced its third quarter 2026 financial results, reporting record total revenues of $226.8 million, an 18% increase compared to the same period last year. The company's four growth products saw a combined revenue increase of 29% to $192.2 million, driven by strong sales of Qelbree®, GOCOVRI®, ZURZUVAE®, and ONAPGO™. The merger with Indivior Pharmaceuticals is expected to close on November 2, 2026. Supernus also raised its full-year 2026 revenue guidance to $875 - $900 million.
Key Highlights
- Supernus Pharmaceuticals reported Q3 2026 total revenues of $226.8 million, an 18% increase year-over-year.
- Combined revenues of four growth products increased 29% to $192.2 million in Q3 2026.
- Net sales of Qelbree increased 12% to $90.8 million in Q3 2026.
- GOCOVRI net sales reached an all-time high of $42.6 million in Q3 2026, a 4% increase.
- ONAPGO net sales were $17.1 million in Q3 2026, a 151% increase.
- Collaboration revenue from ZURZUVAE was $41.7 million in Q3 2026, a 107% increase.
- Merger with Indivior Pharmaceuticals expected to close on November 2, 2026.
- Full year 2026 total revenue guidance raised to $875 - $900 million.
Price Impact
More from SUPN